338 related articles for article (PubMed ID: 15619136)
1. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
Hauben M; Reich L; Chung S
Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
[TBL] [Abstract][Full Text] [Related]
2. Safety related drug-labelling changes: findings from two data mining algorithms.
Hauben M; Reich L
Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
[TBL] [Abstract][Full Text] [Related]
3. Endotoxin-like reactions with intravenous gentamicin: results from pharmacovigilance tools under investigation.
Hauben M; Reich L
Infect Control Hosp Epidemiol; 2005 Apr; 26(4):391-4. PubMed ID: 15865275
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
5. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
Hauben M; Horn S; Reich L
Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
[TBL] [Abstract][Full Text] [Related]
6. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Hauben M; Reich L; Gerrits CM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
[TBL] [Abstract][Full Text] [Related]
7. Illusions of objectivity and a recommendation for reporting data mining results.
Hauben M; Reich L; Gerrits CM; Younus M
Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
[TBL] [Abstract][Full Text] [Related]
8. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
Hochberg AM; Hauben M
Clin Pharmacol Ther; 2009 Jun; 85(6):600-6. PubMed ID: 19322165
[TBL] [Abstract][Full Text] [Related]
9. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
[TBL] [Abstract][Full Text] [Related]
10. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
Szarfman A; Machado SG; O'Neill RT
Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
14. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
15. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
18. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.
Hauben M; Horn S; Reich L; Younus M
Int J Infect Dis; 2007 Sep; 11(5):417-22. PubMed ID: 17336566
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
20. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
Hauben M; Reich L
J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
